Brokerages Set Elanco Animal Health Incorporated (NYSE:ELAN) Price Target at $23.78

Elanco Animal Health Incorporated (NYSE:ELAN) has been given a consensus recommendation of “Moderate Buy” by the thirteen analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, seven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $23.7778.

ELAN has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Monday, December 22nd. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, December 10th. Morgan Stanley upped their target price on shares of Elanco Animal Health from $18.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, December 18th. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 20th. Finally, Argus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Wednesday, November 19th.

Elanco Animal Health Trading Up 1.0%

Shares of ELAN stock opened at $22.61 on Friday. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $23.70. The company has a market cap of $11.23 billion, a PE ratio of 376.81, a price-to-earnings-growth ratio of 3.46 and a beta of 1.86. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $22.10 and its two-hundred day moving average is $18.70.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. Elanco Animal Health’s revenue was up 10.4% compared to the same quarter last year. During the same period last year, the business posted $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Equities analysts predict that Elanco Animal Health will post 0.91 EPS for the current year.

Insider Transactions at Elanco Animal Health

In other news, CFO Robert M. Vanhimbergen acquired 6,950 shares of Elanco Animal Health stock in a transaction on Thursday, December 11th. The stock was bought at an average price of $21.64 per share, for a total transaction of $150,398.00. Following the transaction, the chief financial officer owned 124,233 shares of the company’s stock, valued at $2,688,402.12. The trade was a 5.93% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Rajeev A. Modi acquired 4,500 shares of the stock in a transaction dated Thursday, December 11th. The shares were purchased at an average price of $21.33 per share, for a total transaction of $95,985.00. Following the completion of the transaction, the insider owned 123,082 shares of the company’s stock, valued at $2,625,339.06. This trade represents a 3.79% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 43,450 shares of company stock worth $937,883 over the last 90 days. Insiders own 0.89% of the company’s stock.

Institutional Trading of Elanco Animal Health

Institutional investors have recently made changes to their positions in the business. Hsbc Holdings PLC lifted its holdings in Elanco Animal Health by 434.2% in the second quarter. Hsbc Holdings PLC now owns 126,334 shares of the company’s stock valued at $1,801,000 after buying an additional 102,686 shares during the period. Norges Bank acquired a new stake in shares of Elanco Animal Health in the 2nd quarter valued at approximately $12,502,000. Comerica Bank increased its stake in Elanco Animal Health by 46.4% in the first quarter. Comerica Bank now owns 49,680 shares of the company’s stock valued at $522,000 after purchasing an additional 15,754 shares in the last quarter. Equitable Trust Co. increased its position in shares of Elanco Animal Health by 65.5% in the 2nd quarter. Equitable Trust Co. now owns 248,108 shares of the company’s stock valued at $3,543,000 after buying an additional 98,172 shares in the last quarter. Finally, Yousif Capital Management LLC raised its position in shares of Elanco Animal Health by 1,333.7% during the third quarter. Yousif Capital Management LLC now owns 168,133 shares of the company’s stock worth $3,386,000 after purchasing an additional 156,406 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.